{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:17:48Z","timestamp":1776352668894,"version":"3.51.2"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Chronic kidney disease (CKD) is a growing global public health challenge worldwide. In Mexico, CKD prevalence is alarmingly high and remains a leading cause of morbidity and mortality. Diabetic kidney disease (DKD), a severe complication of diabetes, is a leading determinant of CKD. The escalating diabetes prevalence and the complex regional landscape in Mexico underscore the pressing need for tailored strategies to reduce the burden of CKD. This narrative review, endorsed by the Mexican College of Nephrologists, aims to provide a brief overview and specific strategies for healthcare providers regarding preventing, screening, and treating CKD in patients living with diabetes in all care settings. The key topics covered in this review include the main cardiometabolic contributors of DKD (overweight\/obesity, hyperglycemia, arterial hypertension, and dyslipidemia), the identification of kidney-related damage markers, and the benefit of novel pharmacological approaches based on Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA). We also address the potential use of novel therapies based on Mineralocorticoid Receptor Antagonists (MRAs) and their future implications. Emphasizing the importance of multidisciplinary treatment, this narrative review aims to promote strategies that may be useful to alleviate the burden of DKD and its associated complications. It underscores the critical role of healthcare providers and advocates for collaborative efforts to enhance the quality of life for millions of patients affected by DKD.<\/jats:p>","DOI":"10.3389\/fmed.2024.1376115","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:22:13Z","timestamp":1718770933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists"],"prefix":"10.3389","volume":"11","author":[{"given":"Silvia","family":"Palomo-Pi\u00f1\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Armando","family":"Aguilar-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan Samuel","family":"Ch\u00e1vez-I\u00f1iguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Ericel","family":"Hern\u00e1ndez-Arellanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Antonio","family":"Mariano-Murga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Flores-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Juana","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Pazos-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Trevi\u00f1o-Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora E.","family":"Guillen-Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Manolo","family":"Ramos-Gordillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Trinidad-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neftali Eduardo","family":"Antonio-Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","article-title":"The epidemiology of diabetic kidney Disease","volume":"2","author":"Hoogeveen","year":"2022","journal-title":"Kidney Dial"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US renal data system 2019 annual data report: epidemiology of kidney Disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of Disease study 2017","volume":"395","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/2315607","article-title":"Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a Meta-analysis of observational studies","volume":"2020","author":"Zhang","year":"2020","journal-title":"J Diabetes Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"857930","DOI":"10.3389\/fendo.2022.857930","article-title":"Normal weight obesity and Cardiometabolic risk factors: a systematic review and Meta-analysis","volume":"13","author":"Mohammadian Khonsari","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jcmg.2009.12.004","article-title":"Cardiac remodeling in obesity: time for a new paradigm","volume":"3","author":"Litwin","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.120.11941","article-title":"Angiotensin II type 2 receptor: a target for protection against hypertension, metabolic dysfunction, and organ remodeling","volume":"77","author":"Fatima","year":"2021","journal-title":"Hypertension"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2605.2007.00858.x","article-title":"Effects of endocrine disruptors on obesity","volume":"31","author":"Newbold","year":"2008","journal-title":"Int J Androl"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1053\/j.ajkd.2005.08.015","article-title":"Association between body mass index and CKD in apparently healthy men","volume":"46","author":"Gelber","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet Lond Engl."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.kint.2017.11.034","article-title":"Advanced glycation end products in the pathogenesis of chronic kidney disease","volume":"93","author":"Rabbani","year":"2018","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1515\/bmc-2016-0021","article-title":"Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy","volume":"7","author":"Kumar Pasupulati","year":"2016","journal-title":"Biomol Concepts"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.3390\/ijms20153711","article-title":"Oxidative stress in the pathogenesis and evolution of chronic kidney Disease: untangling Ariadne\u2019s thread","volume":"20","author":"Duni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney Disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1161\/HYPERTENSIONAHA.116.08560","article-title":"Synergistic interaction of hypertension and diabetes in promoting kidney injury and the role of endoplasmic reticulum stress","volume":"69","author":"Wang","year":"2017","journal-title":"Hypertens"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1073\/pnas.82.17.5963","article-title":"Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy","volume":"82","author":"Zatz","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"hpae 024","DOI":"10.1093\/ajh\/hpae024","article-title":"Patients living with arterial hypertension in Mexico: first insights of the Mexican registry of arterial hypertension (RIHTA study)","author":"Palomo-Pi\u00f1\u00f3n","year":"2024","journal-title":"Am J Hypertens"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/1573402111666150529130922","article-title":"Oxidative stress and antioxidants in hypertension-a current review","volume":"11","author":"Sinha","year":"2015","journal-title":"Curr Hypertens Rev"},{"key":"ref22","first-page":"E8","article-title":"The JNC 8 hypertension guidelines: an in-depth guide","volume":"20","author":"Page","year":"2014","journal-title":"Am J Manag Care"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the Management of Blood Pressure in chronic kidney Disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney Disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e1560","DOI":"10.1097\/MD.0000000000001560","article-title":"Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension","volume":"94","author":"Xu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/ndt\/gfad118","article-title":"Hypertension in chronic kidney disease - treatment standard 2023","volume":"38","author":"Georgianos","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney Disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1177\/1060028019843644","article-title":"Nondihydropyridine Calcium Channel blockers for the treatment of proteinuria: a review of the literature","volume":"53","author":"Steuber","year":"2019","journal-title":"Ann Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.24875\/RIC.18002573","article-title":"Dyslipidemia in MEXICO, a CALL for action","volume":"70","author":"Rivas-Gomez","year":"2018","journal-title":"Rev Investig Clin"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.endinu.2019.04.010","article-title":"The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous region of Cantabria","volume":"67","author":"D\u00edaz Vera","year":"2020","journal-title":"Endocrinol Diabetes Nutr"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e0142291","DOI":"10.1371\/journal.pone.0142291","article-title":"Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton Organization in Podocytes","volume":"10","author":"Mart\u00ednez-Garc\u00eda","year":"2015","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/14728222.2017.1369961","article-title":"New perspectives on CKD-induced dyslipidemia","volume":"21","author":"Berm\u00fadez-L\u00f3pez","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","article-title":"Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease","volume":"2","author":"De Vries","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40620-019-00650-x","article-title":"Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian diabetes society and the Italian Society of Nephrology on \u201cthe natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function\u201d","volume":"33","author":"Pugliese","year":"2020","journal-title":"J Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/ki.2014.98","article-title":"Progressive diabetic nephropathy. How useful is microalbuminuria?: contra","volume":"86","author":"Mac Isaac","year":"2014","journal-title":"Kidney Int"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jdi.12533","article-title":"Clinical predictive factors in diabetic kidney disease progression","volume":"8","author":"Radcliffe","year":"2017","journal-title":"J Diabetes Investig"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.kint.2023.08.008","article-title":"Measuring albuminuria or proteinuria: does one answer fit all?","volume":"104","author":"Harrison","year":"2023","journal-title":"Kidney Int"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.2337\/dc13-0190","article-title":"Derivation and validation of a renal risk score for people with type 2 diabetes","volume":"36","author":"Elley","year":"2013","journal-title":"Diabetes Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2215\/CJN.07650711","article-title":"Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function","volume":"7","author":"Zoppini","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes Management in Chronic Kidney Disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"871272","DOI":"10.3389\/fendo.2022.871272","article-title":"Comparison of Nonalbuminuric and Albuminuric diabetic kidney Disease among patients with type 2 diabetes: a systematic review and Meta-analysis","volume":"13","author":"Shi","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.2215\/CJN.02180311","article-title":"Metabolic syndrome and kidney disease: a systematic review and meta-analysis","volume":"6","author":"Thomas","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.nephro.2018.02.007","article-title":"Prognosis and treatment of diabetic nephropathy: recent advances and perspectives","volume":"14","author":"Rossing","year":"2018","journal-title":"Nephrol Ther"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41598-017-18595-1","article-title":"Defining phenotypes in diabetic nephropathy: a novel approach using a cross-sectional analysis of a single Centre cohort","volume":"8","author":"Montero","year":"2018","journal-title":"Sci Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10157-020-01881-0","article-title":"Nonproteinuric diabetic kidney disease","volume":"24","author":"Yamanouchi","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"ref47","first-page":"99","article-title":"Correlation between cystatin C and retinopathy of type-two diabetes mellitus patients","volume":"31","author":"Qian","year":"2017","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1055\/s-0035-1555774","article-title":"Serum cystatin C levels are positively associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes","volume":"123","author":"Chung","year":"2015","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1590\/1516-3180.2020.0707.r1.150321","article-title":"Performance of the CKD-EPI and MDRD equations for estimating glomerular filtration rate: a systematic review of Latin American studies","volume":"139","author":"Bra\u00f1ez-Condorena","year":"2021","journal-title":"S\u00e3o Paulo Med J"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1053\/j.ajkd.2009.02.011","article-title":"GFR estimation in Japan and China: what accounts for the difference?","volume":"53","author":"Rule","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.7326\/0003-4819-157-7-201210020-00003","article-title":"Two novel equations to estimate kidney function in persons aged 70 years or older","volume":"157","author":"Schaeffner","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.archger.2017.12.007","article-title":"Estimation of the glomerular filtration rate in older individuals with serum creatinine-based equations: a systematic comparison between CKD-EPI and BIS1","volume":"75","author":"Oscanoa","year":"2018","journal-title":"Arch Gerontol Geriatr"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ndt\/gfv454","article-title":"An estimated glomerular filtration rate equation for the full age spectrum","volume":"31","author":"Pottel","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","article-title":"Update on cystatin C: incorporation into clinical practice","volume":"62","author":"Shlipak","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ki.1985.205","article-title":"Limitations of creatinine as a filtration marker in glomerulopathic patients","volume":"28","author":"Shemesh","year":"1985","journal-title":"Kidney Int"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/ki.2012.169","article-title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C","volume":"82","author":"Schwartz","year":"2012","journal-title":"Kidney Int"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2337\/diabetes.54.10.2983","article-title":"Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes","volume":"54","author":"Araki","year":"2005","journal-title":"Diabetes"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/ASN.2006080872","article-title":"Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes","volume":"18","author":"Perkins","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.2337\/dc13-0281","article-title":"Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria","volume":"36","author":"Yokoyama","year":"2013","journal-title":"Diabetes Care"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC study","volume":"11","author":"De Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e000902","DOI":"10.1136\/bmjdrc-2019-000902","article-title":"Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan","volume":"8","author":"Yoshida","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e001157","DOI":"10.1136\/bmjdrc-2019-001157","article-title":"Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy","volume":"8","author":"Furuichi","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of Diabetes Mellitus in patients with CKD: Core curriculum 2022","volume":"79","author":"Hahr","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12916-022-02539-2","article-title":"New strategies to improve clinical outcomes for diabetic kidney disease","volume":"20","author":"Forst","year":"2022","journal-title":"BMC Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney Disease: improving global outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diacare.10.1.1","article-title":"Diabetes control and complications trial (DCCT): results of feasibility study. The DCCT research group","volume":"10","year":"1987","journal-title":"Diabetes Care"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"20028","DOI":"10.1038\/srep20028","article-title":"Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney Disease","volume":"6","author":"Kuo","year":"2016","journal-title":"Sci Rep"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00125-013-2854-8","article-title":"Change in HbA1c over 3 years does not improve the prediction of cardiovascular disease over and above HbA1c measured at a single time point","volume":"56","author":"Chamnan","year":"2013","journal-title":"Diabetologia"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/jcm4050948","article-title":"Hypoglycemia in patients with diabetes and renal Disease","volume":"4","author":"Alsahli","year":"2015","journal-title":"J Clin Med"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"e002300","DOI":"10.1136\/bmjdrc-2021-002300","article-title":"Management of type 2 diabetes in chronic kidney disease","volume":"9","author":"Triozzi","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"844","DOI":"10.2215\/CJN.11650918","article-title":"Hypoglycemia in people with type 2 diabetes and CKD","volume":"14","author":"Ahmad","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/1753-0407.12624","article-title":"How does CKD affect HbA1c?","volume":"10","author":"Bloomgarden","year":"2018","journal-title":"J Diabetes"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2337\/dc22-1399","article-title":"The impact of Carbamylation and Anemia on HbA1c\u2019s association with renal outcomes in patients with diabetes and chronic kidney Disease","volume":"46","author":"Tang","year":"2023","journal-title":"Diabetes Care"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.cca.2012.04.025","article-title":"Glycated albumin in diabetic patients with chronic kidney disease","volume":"413","author":"Zheng","year":"2012","journal-title":"Clin Chim Acta"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"m 4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","article-title":"The pleiotropic effects of sodium\u2013glucose Cotransporter-2 inhibitors: beyond the glycemic benefit","volume":"10","author":"Patel","year":"2019","journal-title":"Diabetes Ther"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/ndt\/gfx350","article-title":"Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease","volume":"33","author":"Dekkers","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2666-7568(23)00032-6","article-title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","volume":"4","author":"Pratley","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/dom.14288","article-title":"A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: the N-ISM study","volume":"23","author":"Kitazawa","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","article-title":"Efficacy and safety of Luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial","volume":"12","author":"Seino","year":"2021","journal-title":"Diabetes Ther"},{"key":"ref93","first-page":"45","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Fed Pract"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"204201882211124","DOI":"10.1177\/20420188221112490","article-title":"The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice","volume":"13","author":"von Scholten","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s13300-023-01391-8","article-title":"Comparative efficacy of novel antidiabetic drugs on albuminuria outcomes in type 2 diabetes: a systematic review","volume":"14","author":"Liu","year":"2023","journal-title":"Diabetes Ther"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/ckj\/sfab096","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria","volume":"14","author":"Delanaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"253","DOI":"10.24875\/ACM.20000183","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review","volume":"92","author":"Ch\u00e1vez-I\u00f1iguez","year":"2022","journal-title":"Arch Cardiol Mex"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneph.2012.279","article-title":"Cardiorenal syndrome: pathophysiology and potential targets for clinical management","volume":"9","author":"Hatamizadeh","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ki.1989.51","article-title":"Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems","volume":"35","author":"Gonzalez-Campoy","year":"1989","journal-title":"Kidney Int"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","article-title":"Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease","volume":"37","author":"Shiigai","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"F1178","DOI":"10.1152\/ajprenal.00532.2009","article-title":"Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11\u03b2-HSD activity","volume":"298","author":"Brem","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/ndt\/gfr561","article-title":"A study of the natural history of diabetic kidney disease (DKD)","volume":"27","author":"Altemtam","year":"2012","journal-title":"Nephrol Dial"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","article-title":"Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Sueta","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone\u2019s Antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertens"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"e2236123","DOI":"10.1001\/jamanetworkopen.2022.36123","article-title":"Association of Finerenone use with Reduction in treatment-emergent pneumonia and COVID-19 adverse events among patients with type 2 diabetes and chronic kidney Disease: a FIDELITY pooled secondary analysis","volume":"5","author":"Pitt","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","article-title":"Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose Cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with Finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"ref130","doi-asserted-by":"crossref","DOI":"10.2147\/TCRM.S325916","article-title":"Role of Finerenone in the treatment of diabetic kidney Disease: patient selection and clinical perspectives","author":"Shaikh","year":"2022","journal-title":"Ther Clin Risk Manag"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1376115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:22:20Z","timestamp":1718770940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1376115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":130,"alternative-id":["10.3389\/fmed.2024.1376115"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1376115","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"article-number":"1376115"}}